Advancing 3D cell-culture-based technology to deliver more biologically relevant in vitro insights
InSphero sets the global gold standard for advanced, yet easy-to-use 3D tissue-based assay solutions for predictive compound classification. Our customers in the pharmaceutical, biotech, cosmetics and chemical/environmental industries rely on our robust, convenient and internationally recognized solutions to make informed decisions during discovery and development.
Creating a healthier society by enabling life science companies to invent safer, novel compounds faster and more efficiently, without the use of laboratory animals.
- Honesty, integrity and respect for all employees, customers and suppliers
- Contribution to the development of safe, effective compounds that improve quality of life
- Integrity and precision in our scientific work to the highest ethical standards
- Open communication and transparency for all employees
- Recognition and reward of achievement through creativity, risk taking, process improvements, and innovation
- Adaptability and flexibility in the workplace
InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight™ Microtissues and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreatic islet, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology (with a focus on immuno-oncology). All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized format, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and onsite training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models.
InSphero 3D InSight™ solutions drive significant findings in peer-reviewed journals, through collaborative industry initiatives such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies.
Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards. In addition, InSphero has implemented and maintains a quality management system that has been verified to fulfill the requirements of the ISO 9001:2015 standard.